1. Kessler R C, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication[J]. Arch Gen Psychiatry, 2005, 62(6): 593-602.
2. Austin M P, Kildea S, Sullivan E. Maternal mortality and psychiatric morbidity in the perinatal period: challenges and opportunities for prevention in the Australian setting[J]. Med J Aust, 2007, 186(7): 364-367.
3. Woody C A, Ferrari A J, Siskind D J, et al. A systematic review and meta-regression of the prevalence and incidence of perinatal depression[J]. J Affect Disord, 2017, 219: 86-92.
4. El M H, Jaddoe V W, Hudziak J J, et al. Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes[J]. Arch Gen Psychiatry, 2012, 69(7): 706-714.
5. Huang H, Coleman S, Bridge J A, et al. A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight[J]. Gen Hosp Psychiatry, 2014, 36(1): 13-18.
6. Myles N, Newall H, Ward H, et al. Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations[J]. Aust N Z J Psychiatry, 2013, 47(11): 1002-1012.
7. Gemmel M, Bogi E, Ragan C, et al. Perinatal selective serotonin reuptake inhibitor medication (SSRI) effects on social behaviors, neurodevelopment and the epigenome[J]. Neurosci Biobehav Rev, 2018, 85: 102-116.
8. Popa D, Lena C, Alexandre C, et al. Lasting syndrome of depression produced by reduction in serotonin uptake during postnatal development: evidence from sleep, stress, and behavior[J]. J Neurosci, 2008, 28(14): 3546-3554.
9. Gouvea T S, Morimoto H K, de Faria M J, et al. Maternal exposure to the antidepressant fluoxetine impairs sexual motivation in adult male mice[J]. Pharmacol Biochem Behav, 2008, 90(3): 416-419.
10. Favaro P, Costa L C, Moreira E G. Maternal fluoxetine treatment decreases behavioral response to dopaminergic drugs in female pups[J]. Neurotoxicol Teratol, 2008, 30(6): 487-494.
11. Croen L A, Grether J K, Yoshida C K, et al. Antidepressant use during pregnancy and childhood autism spectrum disorders[J]. Arch Gen Psychiatry, 2011, 68(11): 1104-1112.
12. Eriksson M A, Westerlund J, Anderlid B M, et al. First-degree relatives of young children with autism spectrum disorders: some gender aspects[J]. Res Dev Disabil, 2012, 33(5): 1642-1648.
13. Gidaya N B, Lee B K, Burstyn I, et al. In utero exposure to selective serotonin reuptake inhibitors and risk for autism spectrum disorder[J]. J Autism Dev Disord, 2014, 44(10): 2558-2567.
14. Harrington R A, Lee L C, Crum R M, et al. Prenatal SSRI use and offspring with autism spectrum disorder or developmental delay[J]. Pediatrics, 2014, 133(5): e1241-e1248.
15. Hviid A, Melbye M, Pasternak B. Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism[J]. N Engl J Med, 2013, 369(25): 2406-2415.
16. Rai D, Lee B K, Dalman C, et al. Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study[J]. BMJ, 2013, 346: f2059.
17. Sorensen M J, Gronborg T K, Christensen J, et al. Antidepressant exposure in pregnancy and risk of autism spectrum disorders[J]. Clin Epidemiol, 2013, 5: 449-459.
18. Ornoy A. Neurobehavioral risks of SSRIs in pregnancy: Comparing human and animal data[J]. Reprod Toxicol, 2017, 72: 191-200.
19. Viktorin A, Uher R, Reichenberg A, et al. Autism risk following antidepressant medication during pregnancy[J]. Psychol Med, 2017, 47(16): 2787-2796.
20. Kim J Y, Son M J, Son C Y, et al. Environmental risk factors and biomarkers for autism spectrum disorder: an umbrella review of the evidence[J]. Lancet Psychiatry, 2019, 6(7): 590-600.
21. Zhong P, Yuen E Y, Yan Z. Modulation of neuronal excitability by serotonin-NMDA interactions in prefrontal cortex[J]. Mol Cell Neurosci, 2008, 38(2): 290-299.
22. Bright F M, Byard R W, Vink R, et al. Normative distribution of substance P and its tachykinin neurokinin-1 receptor in the medullary serotonergic network of the human infant during postnatal development[J]. Brain Res Bull, 2018, 137: 319-328.
23. Forero A, Rivero O, Waldchen S, et al. Cadherin-13 Deficiency Increases Dorsal Raphe 5-HT Neuron Density and Prefrontal Cortex Innervation in the Mouse Brain[J]. Front Cell Neurosci, 2017, 11: 307.
24.Brown H K. Prenatal Selective Serotonin Reuptake Inhibitor Exposure and Child Neurodevelopment: The Importance of Maternal Mental Illness[J]. J Am Acad Child Adolesc Psychiatry, 2018, 57(3): 151-152.
25.Andalib S, Emamhadi M R, Yousefzadeh-Chabok S, et al. Maternal SSRI exposure increases the risk of autistic offspring: A meta-analysis and systematic review[J]. Eur Psychiatry, 2017, 45: 161-166.
26.Vigod S N, Gomes T, Ray J G. Prenatal Antidepressant Use and Autism Spectrum Disorder-Reply[J]. JAMA, 2017, 318(7): 665.
27. Ackerman S, Schoenbrun S, Hudac C, et al. Interactive Effects of Prenatal Antidepressant Exposure and Likely Gene Disrupting Mutations on the Severity of Autism Spectrum Disorder[J]. J Autism Dev Disord, 2017, 47(11): 3489-3496.
28. Sujan A C, Rickert M E, Oberg A S, et al. Associations of Maternal Antidepressant Use During the First Trimester of Pregnancy With Preterm Birth, Small for Gestational Age, Autism Spectrum Disorder, and Attention-Deficit/Hyperactivity Disorder in Offspring[J]. JAMA, 2017, 317(15): 1553-1562.
29. Malm H, Brown A S, Gissler M, et al. Gestational Exposure to Selective Serotonin Reuptake Inhibitors and Offspring Psychiatric Disorders: A National Register-Based Study[J]. J Am Acad Child Adolesc Psychiatry, 2016, 55(5): 359-366.
30. Lupattelli A, Wood M, Ystrom E, et al. Effect of Time-Dependent Selective Serotonin Reuptake Inhibitor Antidepressants During Pregnancy on Behavioral, Emotional, and Social Development in Preschool-Aged Children[J]. J Am Acad Child Adolesc Psychiatry, 2018, 57(3): 200-208.
31. Oberlander T F, Gingrich J A, Ansorge M S. Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence[J]. Clin Pharmacol Ther, 2009, 86(6): 672-677.
32. Miyazaki K, Narita N, Narita M. Maternal administration of thalidomide or valproic acid causes abnormal serotonergic neurons in the offspring: implication for pathogenesis of autism[J]. Int J Dev Neurosci, 2005, 23(2-3): 287-297.
33. Logue S F, Gould T J. The neural and genetic basis of executive function: attention, cognitive flexibility, and response inhibition[J]. Pharmacol Biochem Behav, 2014, 123: 45-54.
34. Salas C E, Radovic D, Yuen K S, et al. "Opening an emotional dimension in me": changes in emotional reactivity and emotion regulation in a case of executive impairment after left fronto-parietal damage[J]. Bull Menninger Clin, 2014, 78(4): 301-334.
35. Devito T J, Drost D J, Neufeld R W, et al. Evidence for cortical dysfunction in autism: a proton magnetic resonance spectroscopic imaging study[J]. Biol Psychiatry, 2007, 61(4): 465-473.
36. Libero L E, Deramus T P, Lahti A C, et al. Multimodal neuroimaging based classification of autism spectrum disorder using anatomical, neurochemical, and white matter correlates[J]. Cortex, 2015, 66: 46-59.
37. Olivier J D, Valles A, van Heesch F, et al. Fluoxetine administration to pregnant rats increases anxiety-related behavior in the offspring[J]. Psychopharmacology (Berl), 2011, 217(3): 419-432.
38. Kroeze Y, Dirven B, Janssen S, et al. Perinatal reduction of functional serotonin transporters results in developmental delay[J]. Neuropharmacology, 2016, 109: 96-111.
39. Dufour-Rainfray D, Vourc'H P, Le Guisquet A M, et al. Behavior and serotonergic disorders in rats exposed prenatally to valproate: a model for autism[J]. Neurosci Lett, 2010, 470(1): 55-59.
40. Shahrokhi A, Hassanzadeh G, Vousooghi N, et al. The effect of tiagabine on physical development and neurological reflexes and their relationship with the gamma-aminobutyric acid switch in the rat cerebral cortex during developmental stages[J]. Behav Pharmacol, 2013, 24(7): 561-568.
41. Altman J, Sudarshan K. Postnatal development of locomotion in the laboratory rat[J]. Anim Behav, 1975, 23(4): 896-920.
42. Edwards D A, Thompson M L, Burge K G. Olfactory bulb removal vs peripherally induced anosmia: differential effects on the aggressive behavior of male mice[J]. Behav Biol, 1972, 7(6): 823-828.
43. Nathan B P, Yost J, Litherland M T, et al. Olfactory function in apoE knockout mice[J]. Behav Brain Res, 2004, 150(1-2): 1-7.
44. Lu D C, Zhang H, Zador Z, et al. Impaired olfaction in mice lacking aquaporin-4 water channels[J]. FASEB J, 2008, 22(9): 3216-3223.
45. Pahkla R, Harro J, Rago L. Behavioural effects of pinoline in the rat forced swimming, open field and elevated plus-maze tests[J]. Pharmacol Res, 1996, 34(1-2): 73-78.
46. Nadler J J, Moy S S, Dold G, et al. Automated apparatus for quantitation of social approach behaviors in mice[J]. Genes, Brain and Behavior, 2004, 3(5): 303-314.
47. Li Q, Wong J H, Lu G, et al. Gene expression of synaptosomal-associated protein 25 (SNAP-25) in the prefrontal cortex of the spontaneously hypertensive rat (SHR)[J]. Biochim Biophys Acta, 2009, 1792(8): 766-776.
48. Li Q, Leung Y O, Zhou I, et al. Dietary supplementation with n-3 fatty acids from weaning limits brain biochemistry and behavioural changes elicited by prenatal exposure to maternal inflammation in the mouse model[J]. Transl Psychiatry, 2015, 5: e641.
49. Schwarz A J, Danckaert A, Reese T, et al. A stereotaxic MRI template set for the rat brain with tissue class distribution maps and co-registered anatomical atlas: application to pharmacological MRI[J]. Neuroimage, 2006, 32(2): 538-550.
50.Zhang H, Huang M, Gao L, et al. Region-specific cerebral metabolic alterations in streptozotocin-induced type 1 diabetic rats: an in vivo proton magnetic resonance spectroscopy study[J]. J Cereb Blood Flow Metab, 2015, 35(11): 1738-1745.
51. Li S, Wang X, Yang J, et al. Metabolic profile of visual cortex in diabetic rats measured with in vivo proton MRS[J]. NMR Biomed, 2017, 30(11).
52. Li Q, Leung Y O, Zhou I, et al. Dietary supplementation with n-3 fatty acids from weaning limits brain biochemistry and behavioural changes elicited by prenatal exposure to maternal inflammation in the mouse model[J]. Transl Psychiatry, 2015, 5: e641.
53. Katayama H, Nagasu T, Oda Y. Improvement of in-gel digestion protocol for peptide mass fingerprinting by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry[J]. Rapid Commun Mass Spectrom, 2001, 15(16): 1416-1421.
54. Deng M Y, Lam S, Meyer U, et al. Frontal-subcortical protein expression following prenatal exposure to maternal inflammation[J]. PLoS One, 2011, 6(2): e16638.
55.Tischfield M A, Baris H N, Wu C, et al. Human TUBB3 mutations perturb microtubule dynamics, kinesin interactions, and axon guidance[J]. Cell, 2010, 140(1): 74-87.
56.Rosner M, Hengstschlager M. 14-3-3 proteins are involved in the regulation of mammalian cell proliferation[J]. Amino Acids, 2006, 30(1): 105-109.
57.Wang L H, Strittmatter S M. A family of rat CRMP genes is differentially expressed in the nervous system[J]. J Neurosci, 1996, 16(19): 6197-6207.
58.Rostovtseva T K, Tan W, Colombini M. On the role of VDAC in apoptosis: fact and fiction[J]. J Bioenerg Biomembr, 2005, 37(3): 129-142.
59.Hernanz A, de la Fuente M. Characterization of aconitate hydratase from mitochondria and cytoplasm of ascites tumor cells[J]. Biochem Cell Biol, 1988, 66(7): 792-795.
60. Tochio T, Tanaka H, Nakata S, et al. Fructose-1,6-bisphosphate aldolase A is involved in HaCaT cell migration by inducing lamellipodia formation[J]. J Dermatol Sci, 2010, 58(2): 123-129.
61.Coe H, Schneider J D, Dabrowska M, et al. Role of cysteine amino acid residues in calnexin[J]. Mol Cell Biochem, 2012, 359(1-2): 271-281.
62. Park J E, Lee D H, Lee J A, et al. Annexin A3 is a potential angiogenic mediator[J]. Biochem Biophys Res Commun, 2005, 337(4): 1283-1287.
63.Recktenwald C V, Kellner R, Lichtenfels R, et al. Altered detoxification status and increased resistance to oxidative stress by K-ras transformation[J]. Cancer Res, 2008, 68(24): 10086-10093.
64. Tai H C, Schuman E M. Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction[J]. Nat Rev Neurosci, 2008, 9(11): 826-838.
65. Cox A G, Winterbourn C C, Hampton M B. Mitochondrial peroxiredoxin involvement in antioxidant defence and redox signalling[J]. Biochem J, 2009, 425(2): 313-325.
66. Bairy K L, Madhyastha S, Ashok K P, et al. Developmental and behavioral consequences of prenatal fluoxetine[J]. Pharmacology, 2007, 79(1): 1-11.
67. Deiro T C, Carvalho J, Nascimento E, et al. Neonatal exposure to citalopram, a serotonin selective reuptake inhibitor, programs a delay in the reflex ontogeny in rats[J]. Arq Neuropsiquiatr, 2008, 66(3B): 736-740.
68. Bolivar V J. Intrasession and intersession habituation in mice: from inbred strain variability to linkage analysis[J]. Neurobiol Learn Mem, 2009, 92(2): 206-214.
69. Prut L, Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review[J]. Eur J Pharmacol, 2003, 463(1-3): 3-33.
70. Smit-Rigter L A, Noorlander C W, von Oerthel L, et al. Prenatal fluoxetine exposure induces life-long serotonin 5-HT(3) receptor-dependent cortical abnormalities and anxiety-like behaviour[J]. Neuropharmacology, 2012, 62(2): 865-870.
71. Rebello T J, Yu Q, Goodfellow N M, et al. Postnatal day 2 to 11 constitutes a 5-HT-sensitive period impacting adult mPFC function[J]. J Neurosci, 2014, 34(37): 12379-12393.
72.Ansorge M S, Zhou M, Lira A, et al. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice[J]. Science, 2004, 306(5697): 879-881.
73. Lee L J, Lee L J. Neonatal fluoxetine exposure alters motor performances of adolescent rats[J]. Dev Neurobiol, 2012, 72(8): 1122-1132.
74.Zheng J, Xu D F, Li K, et al. Neonatal exposure to fluoxetine and fluvoxamine alteres spine density in mouse hippocampal CA1 pyramidal neurons[J]. Int J Clin Exp Pathol, 2011, 4(2): 162-168.
75. Nagano M, Liu M, Inagaki H, et al. Early intervention with fluoxetine reverses abnormalities in the serotonergic system and behavior of rats exposed prenatally to dexamethasone[J]. Neuropharmacology, 2012, 63(2): 292-300.
76.Rodriguez-Porcel F, Green D, Khatri N, et al. Neonatal exposure of rats to antidepressants affects behavioral reactions to novelty and social interactions in a manner analogous to autistic spectrum disorders[J]. Anat Rec (Hoboken), 2011, 294(10): 1726-1735.
77. Maciag D, Simpson K L, Coppinger D, et al. Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry[J]. Neuropsychopharmacology, 2006, 31(1): 47-57.
78.Clayton A H, El H S, Iluonakhamhe J P, et al. Sexual dysfunction associated with major depressive disorder and antidepressant treatment[J]. Expert Opin Drug Saf, 2014, 13(10): 1361-1374.
79. Montgomery S A, Baldwin D S, Riley A. Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction[J]. J Affect Disord, 2002, 69(1-3): 119-140.
80. Clayton A H, Pradko J F, Croft H A, et al. Prevalence of sexual dysfunction among newer antidepressants[J]. J Clin Psychiatry, 2002, 63(4): 357-366.
81 Rai D, Lee B K, Dalman C, et al. Antidepressants during pregnancy and autism in offspring: population based cohort study[J]. BMJ, 2017, 358: j2811.
82 Kaplan Y C, Keskin-Arslan E, Acar S, et al. Prenatal selective serotonin reuptake inhibitor use and the risk of autism spectrum disorder in children: A systematic review and meta-analysis[J]. Reprod Toxicol, 2016, 66: 31-43.
83.Schoenichen C, Bode C, Duerschmied D. Role of platelet serotonin in innate immune cell recruitment[J]. Front Biosci (Landmark Ed), 2019, 24: 514-526.
84. Chugani D C. Role of altered brain serotonin mechanisms in autism[J]. Mol Psychiatry, 2002, 7 Suppl 2: S16-S17.
85.Makkonen I, Riikonen R, Kokki H, et al. Serotonin and dopamine transporter binding in children with autism determined by SPECT[J]. Dev Med Child Neurol, 2008, 50(8): 593-597.
86.Li X, Zou H, Brown W T. Genes associated with autism spectrum disorder[J]. Brain Res Bull, 2012, 88(6): 543-552.
87. Yang M S, Gill M. A review of gene linkage, association and expression studies in autism and an assessment of convergent evidence[J]. Int J Dev Neurosci, 2007, 25(2): 69-85.
88.Lira A, Zhou M, Castanon N, et al. Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-deficient mice[J]. Biol Psychiatry, 2003, 54(10): 960-971.
89.Klomp A, Vaclavu L, Meerhoff G F, et al. Effects of chronic fluoxetine treatment on neurogenesis and tryptophan hydroxylase expression in adolescent and adult rats[J]. PLoS One, 2014, 9(5): e97603.
90. Baik S Y, Jung K H, Choi M R, et al. Fluoxetine-induced up-regulation of 14-3-3zeta and tryptophan hydroxylase levels in RBL-2H3 cells[J]. Neurosci Lett, 2005, 374(1): 53-57.
91. Simpson K L, Weaver K J, de Villers-Sidani E, et al. Perinatal antidepressant exposure alters cortical network function in rodents[J]. Proc Natl Acad Sci U S A, 2011, 108(45): 18465-18470.
92. Baslow M H. Evidence that the tri-cellular metabolism of N-acetylaspartate functions as the brain's "operating system": how NAA metabolism supports meaningful intercellular frequency-encoded communications[J]. Amino Acids, 2010, 39(5): 1139-1145.
93.Walecki J, Barcikowska M, Cwikla J B, et al. N-acetylaspartate, choline, myoinositol, glutamine and glutamate (glx) concentration changes in proton MR spectroscopy (1H MRS) in patients with mild cognitive impairment (MCI)[J]. Med Sci Monit, 2011, 17(12): T105-T111.
94. Fujii E, Mori K, Miyazaki M, et al. Function of the frontal lobe in autistic individuals: a proton magnetic resonance spectroscopic study[J]. J Med Invest, 2010, 57(1-2): 35-44.
95.Mori K, Toda Y, Ito H, et al. A proton magnetic resonance spectroscopic study in autism spectrum disorders: amygdala and orbito-frontal cortex[J]. Brain Dev, 2013, 35(2): 139-145.
96.Horder J, Lavender T, Mendez M A, et al. Reduced subcortical glutamate/glutamine in adults with autism spectrum disorders: a [(1)H]MRS study[J]. Transl Psychiatry, 2014, 4: e364.
97.Wang Z, Li W, Chen J, et al. Proteomic analysis reveals energy metabolic dysfunction and neurogenesis in the prefrontal cortex of a lipopolysaccharide-induced mouse model of depression[J]. Mol Med Rep, 2016, 13(2): 1813-1820.
98. Gellen B, Volgyi K, Gyorffy B A, et al. Proteomic investigation of the prefrontal cortex in the rat clomipramine model of depression[J]. J Proteomics, 2017, 153: 53-64.
99.Rose S, Melnyk S, Pavliv O, et al. Evidence of oxidative damage and inflammation associated with low glutathione redox status in the autism brain[J]. Transl Psychiatry, 2012, 2: e134.
100. Focking M, Lopez L M, English J A, et al. Proteomic and genomic evidence implicates the postsynaptic density in schizophrenia[J]. Mol Psychiatry, 2015, 20(4): 424-432.
101.Aitken A. 14-3-3 proteins: a historic overview[J]. Semin Cancer Biol, 2006, 16(3): 162-172.
102. Bruno D L, Anderlid B M, Lindstrand A, et al. Further molecular and clinical delineation of co-locating 17p13.3 microdeletions and microduplications that show distinctive phenotypes[J]. J Med Genet, 2010, 47(5): 299-311.
103. Fromer M, Pocklington A J, Kavanagh D H, et al. De novo mutations in schizophrenia implicate synaptic networks[J]. Nature, 2014, 506(7487): 179-184.
104. Wong A H, Likhodi O, Trakalo J, et al. Genetic and post-mortem mRNA analysis of the 14-3-3 genes that encode phosphoserine/threonine-binding regulatory proteins in schizophrenia and bipolar disorder[J]. Schizophr Res, 2005, 78(2-3): 137-146.
105. Grover D, Verma R, Goes F S, et al. Family-based association of YWHAH in psychotic bipolar disorder[J]. Am J Med Genet B Neuropsychiatr Genet, 2009, 150B(7): 977-983.
106. Pagan C, Goubran-Botros H, Delorme R, et al. Disruption of melatonin synthesis is associated with impaired 14-3-3 and miR-451 levels in patients with autism spectrum disorders[J]. Sci Rep, 2017, 7(1): 2096.
107. Pagan C, Delorme R, Callebert J, et al. The serotonin-N-acetylserotonin-melatonin pathway as a biomarker for autism spectrum disorders[J]. Transl Psychiatry, 2014, 4: e479.
108. Cheah P S, Ramshaw H S, Thomas P Q, et al. Neurodevelopmental and neuropsychiatric behaviour defects arise from 14-3-3zeta deficiency[J]. Mol Psychiatry, 2012, 17(4): 451-466.
109. Xu X, Jaehne E J, Greenberg Z, et al. 14-3-3zeta deficient mice in the BALB/c background display behavioural and anatomical defects associated with neurodevelopmental disorders[J]. Sci Rep, 2015, 5: 12434.
110.Dimatelis J J, Stein D J, Russell V A. Chronic exposure to light reverses the effect of maternal separation on proteins in the prefrontal cortex[J]. J Mol Neurosci, 2013, 51(3): 835-843.
111.Glombik K, Stachowicz A, Trojan E, et al. Evaluation of the effectiveness of chronic antidepressant drug treatments in the hippocampal mitochondria - A proteomic study in an animal model of depression[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2017, 78: 51-60.
112.Yamashita N, Goshima Y. Collapsin response mediator proteins regulate neuronal development and plasticity by switching their phosphorylation status[J]. Mol Neurobiol, 2012, 45(2): 234-246.
113.Chen Y, Sheng H, Xu Y, et al. Activation of CRHR2 exerts an inhibitory effect on the expression of collapsin response mediator protein 3 in hippocampal neurons[J]. Neuropeptides, 2012, 46(2): 93-98.
114.Tsim T Y, Wong E Y, Leung M S, et al. Expression of axon guidance molecules and their related genes during development and sexual differentiation of the olfactory bulb in rats[J]. Neuroscience, 2004, 123(4): 951-965.
115.Quach T T, Massicotte G, Belin M F, et al. CRMP3 is required for hippocampal CA1 dendritic organization and plasticity[J]. FASEB J, 2008, 22(2): 401-409.
116.Nacher J, Soriano S, Varea E, et al. CRMP-4 expression in the adult cerebral cortex and other telencephalic areas of the lizard Podarcis hispanica[J]. Brain Res Dev Brain Res, 2002, 139(2): 285-294.
117.Tsutiya A, Nakano Y, Hansen-Kiss E, et al. Human CRMP4 mutation and disrupted Crmp4 expression in mice are associated with ASD characteristics and sexual dimorphism[J]. Sci Rep, 2017, 7(1): 16812.
118.Parker W, Hornik C D, Bilbo S, et al. The role of oxidative stress, inflammation and acetaminophen exposure from birth to early childhood in the induction of autism[J]. J Int Med Res, 2017, 45(2): 407-438.
119.Khongrum J, Wattanathorn J. Laser Acupuncture Improves Behavioral Disorders and Brain Oxidative Stress Status in the Valproic Acid Rat Model of Autism[J]. J Acupunct Meridian Stud, 2015, 8(4): 183-191.
120.Faber S, Zinn G M, Boggess A, et al. A cleanroom sleeping environment's impact on markers of oxidative stress, immune dysregulation, and behavior in children with autism spectrum disorders[J]. BMC Complement Altern Med, 2015, 15: 71.
121.Al-Amin M M, Rahman M M, Khan F R, et al. Astaxanthin improves behavioral disorder and oxidative stress in prenatal valproic acid-induced mice model of autism[J]. Behav Brain Res, 2015, 286: 112-121.
122.Martin H L, Teismann P. Glutathione--a review on its role and significance in Parkinson's disease[J]. FASEB J, 2009, 23(10): 3263-3272.
123.Butterfield D A, Drake J, Pocernich C, et al. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide[J]. Trends Mol Med, 2001, 7(12): 548-554.
124.Yao J K, Leonard S, Reddy R. Altered glutathione redox state in schizophrenia[J]. Dis Markers, 2006, 22(1-2): 83-93.
125.Andreazza A C, Kauer-Sant'Anna M, Frey B N, et al. Oxidative stress markers in bipolar disorder: a meta-analysis[J]. J Affect Disord, 2008, 111(2-3): 135-144.